First line Treatment - Perjeta for MBC
322 study sites - internationally (outside of the US)
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE) ClinicalTrials.gov Identifier: NCT01572038 http://www.clinicaltrials.gov/ct2/sh...ow_locs=Y#locn |
All times are GMT -7. The time now is 10:30 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021